The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2017 | Targeted therapies for advanced NSCLC
Martin Reck, MD, PhD from the Lungen Clinic Grosshansdorf, Grosshansdorf, Germany discusses how targeted therapies for patients with advanced non-small cell lung cancer (NSCLC) have been a success. The concept of exploiting oncogenic alterations, such as the EGFR mutation or ALK translocation, has improved treatment outcomes. This interview was recorded at the annual meeting of European Lung Cancer Conference (ELCC) in Geneva, Switzerland.
